AbCellera Biologics Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
Consolidated Balance Sheets
(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)
| December 31, 2024 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $156,325 | $128,513 |
| Marketable securities | 469,289 | 405,313 |
| Total cash, cash equivalents, and marketable securities | 625,614 | 533,826 |
| Accounts and accrued receivable | 33,616 | 58,293 |
| Restricted cash | 25,000 | 25,000 |
| Other current assets | 67,140 | 111,113 |
| Total current assets | 751,370 | 728,232 |
| Long-term assets: | ||
| Property and equipment, net | 340,429 | 428,003 |
| Intangible assets, net | 42,113 | 38,381 |
| Goodwill | 47,806 | 47,806 |
| Investments in equity accounted investees | 82,297 | 62,580 |
| Other long-term assets | 96,538 | 51,948 |
| Total long-term assets | 609,183 | 628,718 |
| Total assets | $1,360,553 | $1,356,950 |
| Liabilities and shareholders' equity | ||
| Current liabilities: | ||
| Accounts payable and other current liabilities | $55,004 | $50,781 |
| Contingent consideration payable | 8,087 | — |
| Deferred revenue | 13,521 | 13,526 |
| Total current liabilities | 76,612 | 64,307 |
| Long-term liabilities: | ||
| Operating lease liability | 60,743 | 137,403 |
| Deferred government contributions | 149,893 | 174,453 |
| Deferred tax liability | 10,052 | 9,115 |
| Other long-term liabilities | 7,169 | 4,768 |
| Total long-term liabilities | 227,857 | 325,739 |
| Total liabilities | 304,469 | 390,046 |
| Commitments and contingencies | ||
| Shareholders' equity: | ||
| Common shares: no par value, unlimited authorized shares at December 31, 2024 and December 31, 2025: 295,757,002 and 300,600,710 shares issued and outstanding at December 31, 2024 and December 31, 2025, respectively | 777,171 | 802,341 |
| Additional paid-in capital | 166,361 | 198,279 |
| Accumulated other comprehensive loss | (4,378) | (4,234) |
| Accumulated earnings (deficit) | 116,930 | (29,482) |
| Total shareholders' equity | 1,056,084 | 966,904 |
| Total liabilities and shareholders' equity | $1,360,553 | $1,356,950 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.